

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM549655

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Virtus Pharmaceuticals, LLC		11/15/2019	Limited Liability Company: DELAWARE
Acertis Pharmaceuticals, LLC		11/15/2019	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	White Oak Healthcare Finance, LLC, as Administrative Agent		
Street Address:	1155 Avenue of the Americas, 15th Floor		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10036		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 6			
Property Type	Number	Word Mark	
Serial Number:	86615322	VIRTUS	
Serial Number:	86587871	VIRTUS	
Serial Number:	85760166	NATALVIRT	
Serial Number:	88453270	ACERTIS PHARMACEUTICALS	
Serial Number:	88231895	ACERTIS	
Serial Number:	88300110	FENDIQUE	
CORRESPONDENCE DATA			
Fax Number:	4044435599		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	tlockley@mcguirewoods.com		
Correspondent Name:	Tequira Lockley - Paralegal		
Address Line 1:	1230 Peachtree Street, N.E., Suite 2100		
Address Line 2:	McGuireWoods LLP		
Address Line 4:	Atlanta, GEORGIA 30309		
ATTORNEY DOCKET NUMBER:	2071526.0023		
NAME OF SUBMITTER:	Tequira Lockley		

OP \$165.00 86615322

SIGNATURE:	//Tequira Lockley//
DATE SIGNED:	11/15/2019
Total Attachments: 6 source=Virtus - Trademark Security Agreement#page1.tif source=Virtus - Trademark Security Agreement#page2.tif source=Virtus - Trademark Security Agreement#page3.tif source=Virtus - Trademark Security Agreement#page4.tif source=Virtus - Trademark Security Agreement#page5.tif source=Virtus - Trademark Security Agreement#page6.tif	

TRADEMARK SECURITY AGREEMENT

This TRADEMARK SECURITY AGREEMENT, dated as of November 15, 2019 (this “Agreement”), is made by VIRTUS PHARMACEUTICALS, LLC, a Delaware limited liability company (the “Company”) and ACERTIS PHARMACEUTICALS, LLC, a Delaware limited liability company (“Acertis”, and together with the Company, collectively the “Grantors” and each a “Grantor”), in favor of WHITE OAK HEALTHCARE FINANCE, LLC (“White Oak”), as administrative agent for the Lenders referred to below (in such capacity, together with its successors and permitted assigns, “Administrative Agent”) for all Lenders (as defined in the Loan Agreement referred to below).

WITNESSETH:

WHEREAS, pursuant to that certain Loan and Security Agreement, dated as of November 15, 2019 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”), by and among Grantors, the other Borrowers (as defined in the Loan Agreement) from time to time party thereto, the Subsidiaries of Borrowers from time to time party thereto as Guarantors (as defined in the Loan Agreement), the Lenders (as defined in the Loan Agreement) from time to time party thereto, and Administrative Agent, Lenders have agreed to make extensions of credit to the Borrowers (as defined in the Loan Agreement) upon the terms and subject to the conditions set forth therein;

WHEREAS, each Grantor has granted, pursuant to the Loan Agreement, to Administrative Agent a security interest in all of such Grantor’s Intellectual Property (as defined in the Loan Agreement) other than Excluded Property (as defined therein); and

WHEREAS, pursuant to the Loan Agreement, each Grantor is required to execute and deliver this Agreement to Administrative Agent, for itself and the ratable benefit of the Lenders, in furtherance of such grant;

NOW, THEREFORE, in consideration of the premises and to induce Administrative Agent and Lenders to enter into the Loan Agreement and to induce the Lenders to make their respective extensions of credit to Borrowers thereunder, each Grantor hereby agrees with Administrative Agent as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Loan Agreement, and this Agreement shall be subject to the rules of construction set forth in **Section 1.02** of the Loan Agreement, which rules of construction are incorporated herein by this reference, *mutatis mutandis*.

Section 2. Grant of Security Interest in Intellectual Property Collateral. Each Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Obligations, hereby mortgages, pledges, assigns, and hypothecates to Administrative Agent, for itself and the ratable benefit of the Lenders, and grants to Administrative Agent, for itself and the ratable benefit of the Lenders, a continuing first priority Lien on and security interest in, all of its right, title and interest in, to and under any and all of the following Collateral of such Grantor now existing or at any time hereafter owned, acquired, created, generated, or held by such Grantor (collectively, “Intellectual Property Collateral”), provided that the Intellectual Property Collateral shall not include the Excluded Property (as defined in the Loan Agreement):

(a) All trademarks, trade names, corporate names, business names, trade dress, trade styles, service marks, logos, other source or business identifiers, prints and labels on which any of the foregoing have appeared or appear, designs and general intangibles of like nature (whether registered or unregistered), all registrations and recordings thereof, and all applications in connection therewith, including all registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State or Territory thereof, or any other country or any political subdivision thereof; (b) all reissues, extensions or renewals thereof; and (c) all Goodwill associated with or symbolized by any of the foregoing, now or hereafter existing, created, generated, acquired, or held, including without limitation, those set forth on Exhibit A attached hereto (collectively, the “Trademarks”);

(b) Any and all claims for damages by way of past, present or future infringement of any of the rights included above, with the right, but not the obligation, to sue for and to collect such damages for said use or infringement of the intellectual property rights identified above;

(c) All licenses or other rights to use any of the Trademarks and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(d) All amendments, extensions, renewals and extensions of any of the Trademarks; and

(e) All proceeds and products of the foregoing, including without limitation, license royalties, proceeds of infringement suits, and all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Section 3. Loan Agreement. The security interest granted pursuant to this Agreement is granted in furtherance of and in conjunction with, and not in limitation of, the security interest granted to Administrative Agent, for itself and the ratable benefit of the Lenders, pursuant to the Loan Agreement and Grantor and Administrative Agent hereby acknowledge and agree that the rights and remedies of Administrative Agent with respect to the security interest in the Intellectual Property Collateral made and granted hereby are more fully set forth in the Loan Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. This Agreement is not intended to modify the applicable terms and conditions of the Loan Agreement and to the extent of any conflict, the Loan Agreement shall control.

Section 4. Grantor Remains Liable. Each Grantor hereby agrees that, anything herein to the contrary notwithstanding, such Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with its Intellectual Property Collateral.

Section 5. Counterparts. This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, and each such counterpart shall be deemed to be an original, but all such counterparts shall together constitute but one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart. Receipt by telecopy or in “pdf” format through electronic mail of any executed signature page to this Agreement shall constitute effective delivery of such signature page. This Agreement to the extent signed and delivered by means of a facsimile machine or other electronic transmission (including “pdf”), shall be treated in all manner and respects and for all purposes as an original agreement and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

Section 6. Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS, OTHER THAN NEW YORK GENERAL OBLIGATIONS LAW 5-1401 AND 5-1402.

[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, each Grantor has caused this Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,


VIRTUS PHARMACEUTICALS, LLC,
a Delaware limited liability company
ACERTIS PHARMACEUTICALS, LLC,
a Delaware limited liability company,
each as Grantor

By: 
Name: Debra Cesard
Title: Chief Financial Officer

[Signature Page to Trademark Security Agreement]

ACCEPTED AND AGREED
as of the date first above written:


WHITE OAK HEALTHCARE FINANCE, LLC,
as Administrative Agent

By: 
Name: Daniel Reilly
Title: Managing Director

[Signature Page to Trademark Security Agreement]

EXHIBIT A

Trademarks & Trademark Applications

<u>GRANTOR</u>	<u>MARK</u>	<u>JURISDICTION</u>	<u>SERIAL NO. FILING DATE</u>	<u>REGISTRATION NO. REGISTRATION DATE</u>
VIRTUS PHARMACEUTICALS, LLC	VIRTUS	US	86615322 30-APR-2015	5098228 13-DEC-2016
VIRTUS PHARMACEUTICALS, LLC	VIRTUS	US	86587871 6-APR-2015	5111954 3-JAN-2017
VIRTUS PHARMACEUTICALS, LLC	NATALVIRT	US	85760166 22-OCT-2012	4385595 13-AUG-2013
ACERTIS PHARMACEUTICALS, LLC	ACERTIS PHARMACEUTICALS 	US	88453270 30-MAY-2019	-
ACERTIS PHARMACEUTICALS, LLC	ACERTIS	US	88231895 17-DEC-2018	-
ACERTIS PHARMACEUTICALS, LLC	FENDIQUE	US	88300110 13-FEB-2019	-